DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...
Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...
During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.
Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...
TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...
Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...
The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...
ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) is one of 1,068 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We ...
As previously reported, Guggenheim initiated coverage of ArriVent Biopharma (AVBP) with a Buy rating and $45 price target The late-clinical ...
Indian drug major Sun Pharmaceutical Industries (BSE: 524715) has entered an agreement with Checkpoint Therapeutics (Nasdaq: ...
New phase 3 data presented at ESMO earlier today suggests Tagrisso could be a major step forward in treating patients with EGFR positive non-small cell lung cancer. AstraZeneca has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback